In focus · trending topic

MIN-101 Phase IIb trial

2 stories · following the connections

Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function

By Nasdaq OMXJan 20, 2017, 1:30 PM UTC

Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia

By Nasdaq OMXOct 26, 2016, 12:30 PM UTC